MCID: LYM051
MIFTS: 46

Lymphomatoid Granulomatosis

Categories: Rare diseases, Blood diseases, Immune diseases

Aliases & Classifications for Lymphomatoid Granulomatosis

MalaCards integrated aliases for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 38 50 56 52 69
Lyg 56

Characteristics:

Orphanet epidemiological data:

56
lymphomatoid granulomatosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

Orphanet 56 ORPHA86869
MESH via Orphanet 43 D008230
UMLS via Orphanet 70 C0024307
ICD10 via Orphanet 34 C83.8

Summaries for Lymphomatoid Granulomatosis

NIH Rare Diseases : 50 lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as b lymphocytes. these b cells can build up in the tissues of the body, causing damage to the blood vessels. in many cases of lymphomatoid granulomatosis, the abnormal b cells contain the epstein-barr virus. the disease is more common in men, usually after the fifth decade of life. lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. skin lesions and central nervous system changes such as headaches, seizures, and ataxia may also be seen. rarely, the disorder can affect the kidneys or liver. the cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part. treatment depends on the extent of the disease but may include interferon alfa-2b and combination chemotherapy with rituximab. occasionally, the disorder resolves on its own without treatment. there has been some debate as to whether lymphomatoid granulomatosis should be viewed as a as a b-cell lymphoma or a lymphoproliferative disease or whether it should be viewed merely as a condition that can develop into a b-cell lymphoma. the prognosis is variable, though lymphomatoid granulomatosis can progress and become fatal in some cases.  last updated: 1/4/2017

MalaCards based summary : Lymphomatoid Granulomatosis, also known as lyg, is related to lymphoproliferative syndrome 1 and lymphoproliferative syndrome, x-linked, 1, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Allograft rejection. The drugs Ketamine and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include b cells, lung and bone.

Wikipedia : 72 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Related Diseases for Lymphomatoid Granulomatosis

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 lymphoproliferative syndrome 1 11.2
2 lymphoproliferative syndrome, x-linked, 1 11.0
3 lymphoma 10.4
4 cerebritis 10.2
5 arthritis 10.2
6 hypoglycemia 10.1 GZMB TIA1
7 clivus chondroid chordoma 10.1 GZMB TIA1
8 succinic acidemia lactic acidosis congenital 10.1 GZMB TIA1
9 rubella panencephalitis 10.1 GZMB TIA1
10 gastrointestinal tuberculosis 10.1 GZMB TIA1
11 rheumatoid arthritis 10.1
12 acquired immunodeficiency syndrome 10.1
13 congenital sucrase-isomaltase deficiency with starch intolerance 10.1 GZMB TIA1
14 breast fibroadenosis 10.1 GZMB TIA1
15 pediatric lymphoma 10.1 GZMB TIA1
16 testicular germ cell cancer 10.1 GZMB TIA1
17 macrocephaly, mental retardation, short stature, spastic paraplegia and cns malformations 10.1 GZMB TIA1
18 leukemia 10.1
19 renal hypertension 10.1 GZMB TIA1
20 central sleep apnea 10.1 CXCL9 GZMB
21 polycystic ovary syndrome 10.0 GZMB TIA1
22 mucinous intrahepatic cholangiocarcinoma 10.0 GZMB TIA1
23 plasmodium ovale malaria 10.0 GZMB TIA1
24 mixed cell type cancer 10.0 GZMB TIA1
25 immunodeficiency 11a 10.0 GZMB TIA1
26 hodgkin's lymphoma, lymphocytic-histiocytic predominance 10.0 GZMB TIA1
27 breast ductal adenoma 10.0 IFNA1 IFNA2
28 vasculitis 10.0
29 b-cell lymphomas 10.0
30 polymorphic reticulosis 10.0
31 pneumonia 10.0
32 nuchal bleb, familial 10.0 IFNA1 IFNA2
33 malignant epithelioid hemangioendothelioma 9.9 IFNA1 IFNA2
34 neuropathy 9.9
35 lethal midline granuloma 9.9
36 hematopoietic stem cell transplantation 9.9
37 hemoglobin c disease 9.8 IFNA1 IFNA2
38 congenital nystagmus 9.8 IFNA1 IFNA2
39 lung disease 9.8
40 lymphoblastic leukemia 9.8
41 wiskott-aldrich syndrome 9.8
42 cervicitis 9.8
43 mediastinitis 9.8
44 thrombocythemia 3 9.8 IFNA1 IFNA2
45 noninfectious dermatoses of eyelid 9.8 IFNA1 IFNA2
46 acral lentiginous melanoma 9.8 IFNA1 IFNA2
47 carotid artery dissection 9.7 IFNA1 IFNA2
48 myelofibrosis with myeloid metaplasia, somatic 9.7 IFNA1 IFNA2
49 wegener granulomatosis 9.7
50 griscelli syndrome 9.7

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:



Diseases related to Lymphomatoid Granulomatosis

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

UMLS symptoms related to Lymphomatoid Granulomatosis:


fever, malaise

Drugs & Therapeutics for Lymphomatoid Granulomatosis

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 253)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
3
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
6
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
7
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
8 Orange Approved, Nutraceutical Phase 3
9
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
10
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Analgesics Phase 3,Phase 1,Phase 2
13 Anesthetics Phase 3
14 Anesthetics, Dissociative Phase 3
15 Anesthetics, General Phase 3
16 Anesthetics, Intravenous Phase 3
17 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
18 Excitatory Amino Acid Antagonists Phase 3
19 Excitatory Amino Acids Phase 3
20 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
21 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
22 Amoxicillin-Potassium Clavulanate Combination Phase 3
23 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
24 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 1,Phase 2
26 Antitubercular Agents Phase 3
27 beta-Lactamase Inhibitors Phase 3
28 Clavulanic Acid Phase 3
29 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
30 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
31 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2,Early Phase 1
33 Analgesics, Opioid Phase 3
34 Narcotics Phase 3
35 Adjuvants, Anesthesia Phase 3
36 Liver Extracts Phase 3,Phase 1,Phase 2
37 Antimitotic Agents Phase 3,Phase 2,Phase 1
38 Ferric Compounds Phase 3
39 ferric gluconate Phase 3
40 Hematinics Phase 3,Phase 2
41 Cola Nutraceutical Phase 3,Phase 1,Phase 2
42 Iron Supplement Nutraceutical Phase 3
43
rituximab Approved Phase 1, Phase 2 174722-31-7 10201696
44
Carmustine Approved Phase 1, Phase 2 154-93-8 2578
45
Cytarabine Approved, Investigational Phase 1, Phase 2 147-94-4 6253
46
Etoposide Approved Phase 1, Phase 2, Early Phase 1 33419-42-0 36462
47
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
48
Mechlorethamine Approved Phase 1, Phase 2 51-75-2 4033
49
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
50
Busulfan Approved, Investigational Phase 2,Phase 1,Early Phase 1 55-98-1 2478

Interventional clinical trials:

(show top 50) (show all 180)

id Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Completed NCT00369564 Phase 3 glutamic acid
8 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2 brentuximab vedotin
10 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2 lenalidomide;carmustine;etoposide;cytarabine;melphalan
11 Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
12 Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
13 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
14 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Completed NCT01273766 Phase 2 deferasirox
15 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
16 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
17 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
18 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
19 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
20 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
21 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
22 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
23 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
24 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
25 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
26 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma Completed NCT00054639 Phase 2
27 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
28 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
29 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
30 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
31 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
32 Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
33 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
34 Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
35 Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Completed NCT00365768 Phase 2 Glutamine
36 Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma Completed NCT00238433 Phase 2 busulfan;melphalan;thiotepa
37 Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
38 Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
39 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
40 Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00098566 Phase 2
41 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2 Rituxan and EPOCH
42 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01839916 Phase 2
43 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
45 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies Recruiting NCT01384513 Phase 2 Fludarabine;Busulfan;Cyclophosphamide (CY);Tacrolimus;Mycophenolate mofetil
46 Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Recruiting NCT01609816 Phase 1, Phase 2 Dasatinib
47 Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies Recruiting NCT01643603 Phase 1, Phase 2 Dasatinib
48 Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT00612716 Phase 2 busulfan;cyclophosphamide
49 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
50 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.

Genetic Tests for Lymphomatoid Granulomatosis

Anatomical Context for Lymphomatoid Granulomatosis

MalaCards organs/tissues related to Lymphomatoid Granulomatosis:

39
B Cells, Lung, Bone, Bone Marrow, Liver, T Cells, Kidney

Publications for Lymphomatoid Granulomatosis

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 405)
id Title Authors Year
1
DOCK 8 Deficiency, EBV+ Lymphomatoid Granulomatosis, and Intrafamilial Variation in Presentation. ( 28293550 )
2017
2
The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature. ( 28824078 )
2017
3
Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement. ( 28167690 )
2017
4
Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis. ( 28838746 )
2017
5
Cutaneous human immunodeficiency virus (HIV)-associated lymphomatoid granulomatosis: complete regression following antiretroviral therapy. ( 28188620 )
2017
6
A Rare Case of Pulmonary Lymphomatoid Granulomatosis. ( 28810098 )
2017
7
Lymphomatoid granulomatosis of the brain: A case report. ( 27656321 )
2016
8
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other. ( 27454071 )
2016
9
Lymphomatoid granulomatosis associated with azathioprine use for immune-mediated neuropathy. ( 27671987 )
2016
10
Lymphomatoid granulomatosis coronary vasculitis and cardiomyopathy: Depiction of extent and severity on cardiac CT. ( 27021253 )
2016
11
Pulmonary Lymphomatoid Granulomatosis- a Case Report with Review of Literature. ( 27872542 )
2016
12
Lymphomatoid Granulomatosis: Two Different Phenotypes of Computed Tomography Findings. ( 27768635 )
2016
13
Lymphomatoid Granulomatosis with Paraneoplastic Polymyositis: A Rare Malignancy with Rare Complication. ( 26966605 )
2016
14
Lymphomatoid granulomatosis initially presenting as ulcerated subcutaneous and muscle lesions without pulmonary involvement. ( 27988929 )
2016
15
Lymphomatoid granulomatosis - A rare pulmonary lymphoproliferative disease. ( 26898887 )
2016
16
Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature. ( 27521314 )
2016
17
Low grade pulmonary lymphomatoid granulomatosis with an endobronchial mass. ( 25861350 )
2015
18
Lymphomatoid Granulomatosis. ( 26386275 )
2015
19
Fever, Dry Cough and Exertional Dyspnea: Pulmonary Lymphomatoid Granulomatosis Masquerading as Pneumonia, Granulomatosis with Polyangiitis and Infectious Mononucleosis. ( 26631890 )
2015
20
Pulmonary lymphomatoid granulomatosis. A rare entity in the differential diagnosis of pulmonary nodules. ( 26078192 )
2015
21
A case of lymphomatoid granulomatosis presenting with cutaneous lesions. ( 27051739 )
2015
22
Clinical, imaging and histopathological features of isolated CNS lymphomatoid granulomatosis. ( 25709167 )
2015
23
Granulomatous Lymphoproliferative Disorders: Granulomatous Slack Skin and Lymphomatoid Granulomatosis. ( 26143428 )
2015
24
Pulmonary manifestation of lymphomatoid granulomatosis. ( 26071366 )
2015
25
Epstein-Barr virus-driven B Cell Proliferation with CD4(+) T Cell Expansion: A Lymphomatoid Granulomatosis-like Disease Related to Hyperinterleukin-10 Secretion of Remarkably Favourable Outcome with Rituximab. ( 26332210 )
2015
26
Biopsy-proven muscular involvement of lymphomatoid granulomatosis assessed by (18)FDG-PET Scan. ( 25623523 )
2015
27
Primary cerebral lymphomatoid granulomatosis progressing to methotrexate-associated lymphoproliferative disease under immunosuppressive therapy. ( 25758078 )
2015
28
Pathology in Practice. Lymphomatoid granulomatosis of lung tissue and mediastinal lymph node in a dog. ( 26517613 )
2015
29
Paediatric grade-II lymphomatoid granulomatosis: (18)F-FDG PET/CT monitoring of disease activity. ( 26522001 )
2015
30
Lymphomatoid Granulomatosis with Central Nervous System Involvement Successfully Treated with Cyclophosphamide, High-dose Cytarabine, Dexamethasone, Etoposide, and Rituximab (CHASER therapy) Followed by Brain Irradiation: A Case Study. ( 26096049 )
2015
31
Primary Orbital Lymphomatoid Granulomatosis in a 1-Year-Old Child. ( 26692728 )
2015
32
Lymphomatoid granulomatosis mimicking vasculitis. ( 26382276 )
2015
33
Oral lymphomatoid granulomatosis, the first sign of a 'rare disease': a case report. ( 24886196 )
2014
34
Cutaneous lesions in a CLIPPERS patient: further confusion between CLIPPERS and grade I lymphomatoid granulomatosis. ( 24976067 )
2014
35
Pulmonary lymphomatoid granulomatosis in a 4-year-old girl. ( 25432443 )
2014
36
An eschar and violaceous nodules as the presenting signs of lymphomatoid granulomatosis. ( 25419752 )
2014
37
Lymphomatoid granulomatosis involving the central nervous system: A case report and review of the literature. ( 24932245 )
2014
38
Another rare finding of lymphomatoid granulomatosis on CT scan. ( 24798854 )
2014
39
Lymphomatoid granulomatosis of central nervous system and lung driven by epstein barr virus proliferation: successful treatment with rituximab-containing chemotherapy. ( 24678394 )
2014
40
Childhood Lymphomatoid Granulomatosis: A Report of 2 Cases and Review of the Literature. ( 24390446 )
2014
41
Fatal necrotizing angiotropic Epstein-Barr virus-negative large B-cell lymphoma: a case report with unusual clinicopathological features in-between lymphomatoid granulomatosis and T-cell/histiocyte-rich large B-cell lymphoma. ( 25546693 )
2014
42
Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. ( 25022612 )
2014
43
Lymphomatoid Granulomatosis-A Single Institute Experience: Pathologic Findings and Clinical Correlations. ( 25321327 )
2014
44
Fatal pulmonary lymphomatoid granulomatosis in a patient taking methotrexate for rheumatoid arthritis. ( 23857444 )
2014
45
Orbital lymphomatoid granulomatosis - a rare cause of proptosis. ( 25381000 )
2014
46
Lymphomatoid Granulomatosis Presenting with Cutaneous Involvement: A Case Report with Review of the Literature. ( 25355540 )
2014
47
Pyrexia, Lung nodules, Granulomas: Pulmonary Lymphomatoid Granulomatosis. ( 25332635 )
2014
48
EBV-Negative Cutaneous Lymphomatoid Granulomatosis With Concomitant EBV-Positive Pulmonary Involvement: A Potential Diagnostic and Prognostic Pitfall. ( 25148107 )
2014
49
Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. ( 25130128 )
2014
50
Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis. ( 25674479 )
2014

Variations for Lymphomatoid Granulomatosis

Expression for Lymphomatoid Granulomatosis

Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.

Pathways for Lymphomatoid Granulomatosis

GO Terms for Lymphomatoid Granulomatosis

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.69 GZMB IFNA2 TIA1
2 cytokine-mediated signaling pathway GO:0019221 9.52 IFNA1 IFNA2
3 B cell differentiation GO:0030183 9.49 IFNA1 IFNA2
4 type I interferon signaling pathway GO:0060337 9.48 IFNA1 IFNA2
5 humoral immune response GO:0006959 9.46 IFNA1 IFNA2
6 B cell proliferation GO:0042100 9.43 IFNA1 IFNA2
7 response to exogenous dsRNA GO:0043330 9.4 IFNA1 IFNA2
8 regulation of type I interferon-mediated signaling pathway GO:0060338 9.37 IFNA1 IFNA2
9 T cell activation involved in immune response GO:0002286 9.32 IFNA1 IFNA2
10 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA1 IFNA2
11 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA1 IFNA2
12 defense response to virus GO:0051607 9.13 CXCL9 IFNA1 IFNA2
13 defense response GO:0006952 8.8 CXCL9 IFNA1 IFNA2

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA1 IFNA2
2 cytokine activity GO:0005125 9.13 CXCL9 IFNA1 IFNA2
3 type I interferon receptor binding GO:0005132 8.62 IFNA1 IFNA2

Sources for Lymphomatoid Granulomatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....